Podcasts about Anticoagulant

In this episode, Martin Witzenrath, MD, FERS, and Michele Bartoletti, MD, PhD, discuss the management of mild to moderate COVID-19 in patients who are immunocompromised, including:Initial workup, which may include laboratory tests and/or imagingLatest data on the use of remdesivir or nirmatrelvir plus ritonavir for mild to moderate COVID-19, including considerations for drug–drug interactions Presenters:Martin Witzenrath, MD, FERSMedical DirectorCharite Centrum 12Internal Medicine & DermatologyProfessor and Chair for Respiratory Medicine and Critical CareDepartment of Infectious Disease, Respiratory Medicine and Critical CareCharite Campus Mitte/Campus Virchow Klinikum/Campus Benjamin FranklinCharite – University of BerlinBerlin, GermanyMichele Bartoletti, MD, PhDAssociate Professor of Infectious DiseasesDepartment of Biomedical SciencesHumanitas UniversityPieve Emanuele (MI), ItalyHead of Infectious Diseases UnitIRCCS Humanitas Research HospitalRozzano (MI), Italy Link to full program: https://bit.ly/4gu2gcUDownloadable slides: https://bit.ly/3CGlDBSGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Send us a textDrs. Mithoowani and Siegal discuss new expert guidance for managing severe bleeding in patients taking oral anticoagulants, including identifying those at risk, optimizing supportive measures, treating the source of bleeding, and administering reversal agents. It includes discussion of the algorithm for use at the point of care that helps identify patients at risk of adverse outcomes, optimize supportive measures, treat the source of bleeding, and administer anticoagulant reversal or hemostatic therapies.Abstract: http://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-2464-2887 Full text HTML: http://www.thieme-connect.com/products/ejournals/html/10.1055/a-2464-2887 Full text PDF: http://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-2464-2887.pdf Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care

Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care

Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care

Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care

Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care

Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care

Anticoagulant rodenticide toxicity is one of the most common toxicities reported in dogs and can cause severe bleeding if not identified and managed quickly. These patients often present as emergencies and can require intensive treatment and nursing care - and how to deliver that care is exactly what we'll be diving into in this episode of the Medical Nursing Podcast. ---

It is now uncommon to see warfarin therapy initiated for stroke prevention. However, quality patient care is never a “one-size-fits-all” approach.  New evidence from the FRAIL-AF trial suggests that some of our most vulnerable older adults might be better off maintained on a vitamin K antagonist rather than (automatically) switched to a direct oral anticoagulation (DOAC).   Guest Author:  Matthew Cantrell, PharmD, BCPS Music by Good Talk

Direct oral anticoagulants (DOACs) are commonly used to treat patients with atrial fibrillation and venous thromboembolism. Author James D. Douketis, MD, from McMaster University discusses with JAMA Deputy Editor Kristin L. Walter, MD, MS, the management of DOACs in patients undergoing an elective or emergency surgery or procedure. Related Content: Perioperative Management of Patients Taking Direct Oral Anticoagulants

Un anticoagulant sans risque dʹhémorragie développé entre Genève et Sydney Les brèves du jour Unisanté et lʹUNIL lancent une chaire novatrice dédiée à la coproduction en santé "Tu sais quoi?": Le Conservatoire botanique de Genève fête ses 200 ans Lʹartiste de cirque et contorsionniste Emi Vauthey dans la peau dʹune araignée

Today's sponsor of the Top 10 Anticoagulant Drug Interactions podcast is FreedAI. Freed listens, transcribes, and writes medical documentation for you. FreedAI is offering a discount exclusive to RLP listeners! Users will get $50 off their first month with Freed! Use the discount code: RLPPOD Apixaban is one of the most commonly used anticoagulants and there are some drug interactions you need to be aware of. Take a listen and find out! Warfarin concentrations can substantially be elevated by drugs that inhibit CYP2C9. I cover a few of them in my top 10 anticoagulant drug interactions.

For this topic, we will be discussing the importance of anticoagulant therapy, what it is, what to avoid, what to watch for, and what to report.

In this episode, we review evidence-based guidelines for the emergency reversal of warfarin, dabigatran, and the oral Xa inhibitors (apixaban, edoxaban, and rivaroxaban). Key Concepts Reversal of anticoagulation is indicated in patients with major hemorrhage or when emergency surgery is necessary. Reversal of warfarin (Coumadin®) involves a fast-acting, short-term solution (usually prothrombin complex concentrates [PCC]) and a slower-acting, long-term solution (intravenous vitamin K). Idarucizumab (Praxbind®) is the preferred reversal strategy for dabigatran (Pradaxa®). Idarucizumab is a monoclonal antibody fragment specific that binds and inactivates dabigatran. If idarucizumab is unavailable, PCCs are recommended. Andexanet alfa (Andexxa®) is the preferred reversal strategy for oral Xa inhibitors and has FDA approval specific to apixaban and rivaroxaban. Andexanet alfa is a decoy factor Xa protein with higher binding affinity than human clotting factor Xa. There are several barriers to use with andexanet alfa that has led to low utilization in hospitals. If andexanet alfa is unavailable, PCCs are recommended. References Baugh CW, et al. Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. Ann Emerg Med. 2020;76(4):470-485. Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol. 2019;94(6):697-709. doi:10.1002/ajh.25475 Tomaselli GF, et al. 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020;76(5):594-622.

Anticoagulants can lead to adverse drug events (ADEs) in long-term care facilities. In today's episode, we discuss:Major types of anticoagulants and their basic differencesIndications for starting anticoagulantsWhat steps can be implemented to decrease the risk of adverse drug events associated with warfarinDifferences in dosing protocols between apixaban and rivaroxaban Related links:View video recordingDownload presentation slidesDownload “How to Manage My Blood Thinner”Check out our other interviews by visiting https://www.qualityinsights.org/qin/multimedia  This material was prepared by Quality Insights, a Quality Innovation Network - Quality Improvement Organization under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication number 12SOW-QI-GEN-121423-CC-A 

In this episode, we chat once again with Dr. Jim Neuenschwander about anticoagulant reversal and when to pull the trigger on some of the big dollar agents.

In the latest installment of "Snackisodes on Dangerous Snacks," Lauren and JJ discuss anticoagulant rodenticides. First generation anticoagulants referenced include warfarin, chlorphacinone, coumatetralyl, coumafuryl, diphacinone, fumarin, pindone, and valone. Second generation anticoagulants referenced include brodifacoum, bromadiolone, difethialone, and difenacoum. References: (1) Anticoagulant rodenticide toxicosis. VINcyclopedia of Diseases. Last updated by Brister, J. on 6/5/2021. www.vin.com

Send us a Text Message.Welcome to the first installment of 'Rodenticide Chronicles'. In this eye-opening debut, we dive deep into the world of rodenticides, with a specific focus on the insidious threat of coagulopathy rat baits. We unravel the science behind these lethal compounds, shedding light on how they disrupt blood-clotting mechanisms in rodents and the unintended consequences they unleash on non-target species such as our pets.  Our episode aims to foster awareness, offering insights into safer rodent control practices to keep our pets happy and healthy. Prepare to be enlightened about the hidden perils within your home. In this episode: We'll break down what coagulopathy rat bait is, how it works, and why it's a common choice for rodent control.Dive deep into the science of how these baits disrupt rodents' blood-clotting mechanisms, providing a clear picture of the internal consequences.Learn about the unintended victims including pets who suffer when they ingest these toxic compounds.Get practical tips and guidance on responsible pest control practices that minimize the risks to your pets associated with rodenticides.Support the Show.Connect with me here: https://www.vetsplanationpodcast.com/ https://www.facebook.com/vetsplanation/ https://www.twitter.com/vetsplanations/ https://www.instagram.com/vetsplanation/ https://www.tiktok.com/@vetsplanation/ https://youtube.com/@Vetsplanationpodcast https://www.youtube.com/playlist?list=PLVbvK_wcgytuVECLYsfmc2qV3rCQ9enJK Voluntary donations and Vetsplanation subscription: https://www.paypal.com/donate/?hosted_button_id=DNZL7TUE28SYE https://www.buzzsprout.com/1961906/subscribe

contact@frcapodcast.com

CME credits: 1.50 Valid until: 11-08-2024 Claim your CME credit at https://reachmd.com/programs/cme/anticoagulant-associated-major-bleeding-is-a-significant-problem-how-do-i-address/14733/ The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.

In this episode from ACEP22 in San Francisco, we talk with Dr. Steven Haywood about anticoagulant reversal strategies. ACEP23 registration is open! Save $50 on registration with my promo code FRONTLINE at acep.org/acep23.

Lauren and JJ investigate the cause of neurologic signs in a dog. This episode includes a review of the management of bromethalin ingestion, as well as a review of the management of hypernatremia caused by activated charcoal administration. Sources: (1) Ball, A. (2014). Managing hypernatremia after activated charcoal administration. Veterinary Medicine, 109(4), 126-130. (2) Brister, J., Gwaltney-Brant, S., & Dekker, M. (2021). Bromethalin toxicosis (canine). VINcyclopedia of Diseases. www.vin.com (3) Brister, J., Gwaltney-Brant, S., & Dekker, M. (2021). Anticoagulant rodenticide toxicosis (canine). VINcyclopedia of Diseases. www.vin.com (4) Rothrock, K., & Shell, L. (2021). Hypernatremia (canine). VINcyclopedia of Diseases. www.vin.com (5) Veterinary Information Network (2017). Charcoal, activated. VIN Veterinary Drug Handbook. www.vin.com

CME credits: 1.50 Valid until: 20-06-2024 Claim your CME credit at https://reachmd.com/programs/cme/repletion-or-reversal-optimizing-specific-therapy-for-direct-oral-anticoagulant-doac-related-life-threatening-bleeding-using-real-world-experience/15633/ This enduring activity was originally presented as a satellite symposium which was held during the 9th European Stroke Organisation Conference (ESOC) in Munich, Germany, in May 2023. As the utilization of direct oral anticoagulants (DOACs) increases, there is a parallel increase in major bleeding events, especially intracranial hemorrhages (ICH), requiring hospitalization. Clinicians are not recognizing or distinguishing major from minor bleeding or appropriately employing emergent options to manage major bleeding. Recent solutions for DOAC-related life-threatening bleeding are under-recognized and under-utilized solutions for patients with these life-threatening emergencies. Recently, nationally recognized guidelines have provided clear direction for managing these major bleeding events. As data emerges regarding new approaches to therapy, clinicians need to be aware of these new and effective approaches and assess the benefits and risks associated with each of these approaches. This program focuses on managing ICHs, addresses patient treatment approaches, and distills essential information for everyday clinical practice.

Anticoagulant rodenticide, a quick fix for controlling the rat and mice population, is now having an effect on birds of prey. Today, we talk to A Place Called Hope, a local raptor rehabilitator here in Connecticut, about how it's impacting birds across our state. After ingesting this poison, there is little that can be done to save the life of these birds. We'll hear about legislation to limit the use of these poisons and alternatives to rodenticide. The traditional snap traps aren't the only way to keep out the mice! Later, we hear about efforts to eliminate construction waste, an innovative way to mitigate climate change. GUESTS: Christine Cummings: Executive Director of A Place Called Hope Tom Andersen: Director of Communications, the Connecticut Audubon Society Eve Zuckoff: Climate and Environment Reporter CAI Where We Live is available as a podcast on Apple Podcasts, Spotify, Google Podcasts, Stitcher, or wherever you get your podcasts. Subscribe and never miss an episode.Support the show: http://wnpr.org/donateSee omnystudio.com/listener for privacy information.

A BSH Guideline on the Anticoagulant management of pregnant individuals with mechanical heart valves presented by Dr Will Lester.

On this week's episode of The PQI Podcast, we sit down with Bijoy Telivala, MD, to delve into the realm of anticoagulant therapy.Dr. Telivala, holding Board Certifications in medical oncology, hematology, and internal medicine, currently practices at Cancer Specialists of North Florida in Jacksonville, Florida.Originally from India, Dr. Telivala completed his M.B.B.S. at Lokmanya Tilak Municipal Medical College. He further pursued his medical education and training, earning his Doctor of Medicine from Temple University in Pennsylvania, where he also completed his hematology/oncology fellowship. With a passion for patient care and guidance, Dr. Telivala cherishes the collaborative environment he works in, surrounded by a dedicated team of doctors, nurses, and support staff who share the same primary goal of improving patients' lives."The compassion and empathy offered by the team as CSNF is truly unmatched.”

Anticoagulant rodenticide, a quick fix for controlling the rat and mice population, is now having an effect on birds of prey. Today, we talk to A Place Called Hope, a local raptor rehabilitator here in Connecticut, about how it's impacting birds across our state. After ingesting this poison, there is little that can be done to save the life of these birds. We'll hear about legislation to limit the use of these poisons and alternatives to rodenticide. The traditional snap traps aren't the only way to keep out the mice! Later, we hear from the Connecticut Audubon Society. They are celebrating their 125th anniversary and have a special birding challenge to mark the occasion. We want to hear. Have you seen falcons, hawks and eagles, where you live? GUESTS: Christine Cummings: Executive Director of A Place Called Hope Tom Andersen: Director of Communications, the Connecticut Audubon Society Kathi Borgmann: Communications Manager, Cornell Lab of Ornithology Where We Live is available as a podcast on Apple Podcasts, Spotify, Google Podcasts, Stitcher, or wherever you get your podcasts. Subscribe and never miss an episode.Support the show: http://wnpr.org/donateSee omnystudio.com/listener for privacy information.

This week we review a recent report that focuses on the question of whether the direct thrombin inhibitor, bivalirudin is superior to heparin for the small patient with a paracorporeal device both from a medical and financial perspective. Bivalirudin is 40x the cost of heparin but does that capture all of the costs and how does overall cost differ between patients treated with one versus the other agent? We speak with Assistant Professor of Pediatrics at University of Vermont, Dr. Danielle Burstein about a large PHIS database study she recently published on this topic.DOI:10.1016/j.healun.2022.10.006Also joining us this week is Assistant Professor of Pediatrics at The Icahn School of Medicine at Mount Sinai, Dr. David Ezon to share with us the exciting news about our upcoming, in person, imaging course entitled: The Right Heart - Conversations In Care. The list of speakers is dizzying and come from the worlds of imaging but also interventions - both surgical and cardiac catheterization. Amongst a cast of many world authorities in the worlds of surgery, intervention and imaging, also joining the fun will be two true giants of cardiology and cardiac pathology, namely Dr. Ira Parness and Dr. Richard Van Praagh. For those interested, take a look at the website to learn more at: https://mssm.cloud-cme.com/course/courseoverview?P=5&EID=28135

In this episode of the PRS Global Open Keynotes Podcast, Dr. Karen Evans and Dr. Christopher Attinger discuss the safety of continuing antiplatelet and anticoagulant medications in patients undergoing split skin graft procedures. This episode discusses the following PRS Global Open article: Neither Antiplatelet nor Anticoagulant Therapy Increases Graft Failure after Split-thickness Skin Grafting by Elliot T. Walters, Kevin G. Kim, Paige K. Dekker, Gregory P. Stimac, Shyamin Mehra, Tammer Elmarsafi, John S. Steinberg, Christopher E. Attinger, Paul J. Kim and Karen K. Evans. Read the articles for free on PRSGlobalOpen.com:https://bit.ly/AntiplateletnorAnticoagulant Drs. Evans and Attinger are both Professors in the Department of Plastic and Reconstructive Surgery at Medstar Georgetown University Hospital in Washington, DC. Your host, Dr. Damian Marucci, is a board-certified plastic surgeon and Associate Professor of Surgery at the University of Sydney in Australia. #PRSGlobalOpen #KeynotesPodcast #PlasticSurgery

This video is important for anyone who uses or is affected by these rodenticide policy updates, as it will help you to better understand the changes and their impact. Stephen will also answer any questions that you may have about these changes. Do not miss this second part to this video which addresses new changes…

If you work with Anticoagulant Rodenticides, this is an important video that you won't want to miss! In this video, Wildlife Control Consultant Stephen Vantassel discusses the recent changes to the EPA's anticoagulant rodenticides. These changes may have a significant impact on the way that wildlife control professionals carry out their work. If you're interested…

Bite this episode open and grind your teeth about how much work sucks! Teena joins the ladies again as they talk through some shitty work stories (in all meanings of the word) and a splash of urine therapy. Brave Alliance: https://bravectx.com/Brave Alliance [quicker link to donate](https://www.paypal.com/donate?token=GMQppiQbjmZ2hNSDs8SBuAzfr9xLKgoAsfVvgsYoHEEuBRRh8fkdGLMhduiTa1HUS54v1bBF_fSGrRuG)[Starry Night Adult Prom] (https://www.eventbrite.com/e/starry-night-adult-prom-tickets-409878195717)Write us some of your cringe stories at [nervouslaughterpodcast@gmail.com](mailto:nervouslaughterpodcast@gmail.com)The socials: [Instagram](https://www.instagram.com/nervouslaughterpodcast) | [Facebook](https://www.facebook.com/NervousLaughterPodcast) | [Twitter](https://twitter.com/NervouslaughPod)

Nikitha Yagnala, PharmD (Twitter: @NikithaYagnala) describes laboratory tests used to estimate DOAC plasma levels, reviews current literature exploring the association between DOAC plasma levels and clinical outcomes and outlines appropriate utilization and interpretation of DOAC plasma levels in clinical practice. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter! You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Commentary by Dr. Bonnie Ky

In this episode, Dr. Yeh is joined by lead author Danielle C. Sutzko, MD, MS, from the University of Alabama at Birmingham, and senior author Andrea T. Obi, MD, FACS, from the University of Michigan, both vascular surgeons. They discuss their recent work on outcomes associated with direct oral anticoagulant and vitamin K antagonist use after lower extremity bypass.   Learn more about the Journal of the American College of Surgeons, a monthly peer-reviewed journal publishing original contributions on all aspects of surgery, including scientific articles, collective reviews, experimental investigations, and more.   #JACSOperativeWord

With several choices for oral anticoagulation in Nonvalvular Atrial Fibrillation (NVAF), it is critical for pharmacists to be able to account for patient specific factors when selecting the most appropriate anticoagulant.  To learn more, visit www.ashpadvantage.com/nvaf The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Welcome to the age of PHARMAKIA (Sorcery, witchcraft and drugs i.e. potions) administered by Big Pharmaceutical Magnates et al. All donations and support for the show to be sent to: $Aigner2019(Cashapp).

In this Healthed lecture, cardiologist at GenesisCare, Dr Ali Safaa will go through the current guidelines and the role of the general practitioner in managing anticoagulation and antiplatelet therapy in patients with atrial fibrillation who have recently experienced acute coronary syndromes or undergone a stent procedure. See omnystudio.com/listener for privacy information.

This is Episode 4 of CLOT Conversations from Thrombosis Canada. In this episode Dr Jameel Abdulrehman and David Airdrie are joined by Dr Vinai Bhagirath and Dr Sam Schulman, two of the authors of a recently published paper entitled Carbamazepine, phenytoin, and oral anticoagulants: Drug-drug interaction and clinical events in a retrospective cohort. The paper was published in Research and Practice in Thrombosis and Haemostasis (Res Pract Thromb Haemost. 2022;6:e12650. https://doi.org/10.1002/rth2.12650)The authors discuss the results of the retrospective cohort of patients taking carbamazepine or phenytoin with warfarin or DOACs. In particular, they explore whether there is a relationship between anticoagulant levels and thromboembolic events. Dr Schulman and Dr Bhagirath discuss their perspectives on the issues relevant to each type of anticoagulant when used in patients on anti-seizure medications and what their study added to the understanding of drug-drug interactions.Dr Sam Schulman graduated from Karolinska Institutet, Stockholm, Sweden in 1977 and has worked with coagulation disorders since 1984. Research activities have been clinical studies in venous thromboembolism, in hemophilia and bleeding. He has been a member of the Executive Committee of the World Federation of Hemophilia, was President for the XXV ISTH Congress, Toronto, 2015, is member of the ISTH Council and Treasurer. In 2017 he received Harold R. Roberts medal of the ISTH SSC. He is Director of the Thrombosis Service at Hamilton General Hospital and professor in Medicine at McMaster University, Hamilton, Canada, and at Department of Obstetrics and Gynaecology, The First I.M. Sechenov Moscow State Medical University, Moscow, Russia.Dr Vinai Bhagirath, is a Thrombosis physician at Hamilton Health Sciences and Assistant Professor of Medicine at McMaster University. His research interests include bleeding risk with anticoagulants and clinical measurement of DOAC drug levels. His quality improvement interests include optimization of medical therapy in peripheral artery disease and standardization of periprocedural management of antithrombotic medications. His educational activities include Directorship of Thrombosis Fellowship programs at McMaster, and he is co-chair of the upcoming 2022 THSNA Summit and chair of Thrombosis Canada's Continuing Professional Development committee.Thrombosis Canada Tools related to the content:DOAC Drug Interaction tool: https://thrombosiscanada.ca/wp-uploads/uploads/2021/09/DDI-Tool-Final-English.pdfThrombosis Canada Clinical Guides: https://thrombosiscanada.ca/clinicalguides/Follow us on Twitter: Thrombosis Canada: @ThrombosisCan Sam Schulman: @SamSchulman6Reference: Candeloro, M., Eikelboom, J. W., Chan, N., Bhagirath, V., Douketis, J. D., & Schulman, S. (2022). Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort. Research and Practice in Thrombosis and Haemostasis, 6(2), e12650.Support the showhttps://thrombosiscanada.caTake a look at our healthcare professional and patient resources, videos and publications on thrombosis from the expert members of Thrombosis Canada

In this episode, Dr. Miller will discuss the current treatment options in the reversal of several classes of DOAC medications.

Episode 164: Are you a fan of Raptors or birds of prey? Members of this large group of magnificent birds include hawks, eagles, falcons, and owls. For many of us, seeing raptors in cities and in the wilderness is awe-inspiring.  To learn more about these amazing birds, I am joined by Lisa Owens Viani and Allen Fish, co-founders of the nonprofit Raptors Are the Solution (RATS).  We begin by chatting about the wonders of raptors and why Lisa and Allen have devoted so much of their lives to helping these birds. We then discuss the impact that anticoagulant rodenticides is having on raptors and wildlife. Used worldwide, rodenticides (or rat poisons) affect not only rats, but also large numbers of non-target animals including raptors, bobcats, mountain lions, coyotes, bears, and fish. Rodenticides enter the food chain when animals eat poisoned rodents and receive secondary exposure. Anticoagulant rodenticide ingestion can lead to immune suppression, rodenticide-induced mange, internal hemorrhaging, and death. The overgrowth of rats is caused partly by a lack of predators. We talk about how the poisons we use to control rats end up harming or killing the very predators that are efficient at keeping rodent populations in check.  This interview contains vital information about how we can be better caretakers of our shared environment. All of us can take action to protect raptors and wildlife from anticoagulant rodenticides. What can we do? Start with avoiding the use of toxic rat poisons. Don't make your yard a rat haven. Exclusion, sanitation, and trapping are effective nontoxic methods of rodent control. Visit the Raptors are the Solution website for tips on how to make your yard less attractive to rats, educational resources, an activist toolkit, and more at raptorsarethesolution.org  Guests: Lisa Owens Viani is a long time environmental writer and wildlife advocate. Lisa co-founded and directs Raptors Are The Solution- or RATS, a project of Earth Island Institute.  RATS educates about the ecological role of raptors and the enormous danger that they and all wildlife, as well as pets and children, face from the wide use and availability of anticoagulant rat poisons. RATS partners with other agencies, scientists, municipalities, and NGO's to work toward eliminating toxic rodenticides from the food web. RATS' multi-pronged approach includes public education as well as legislative and legal work to achieve better regulation of these products.  Lisa was honored as the Fund for Wild Nature's Grassroots Activist of 2021 and received a Special Achievement Award on behalf of raptors from the International Owl Center in 2018. Allen Fish is the Associate Director for Conservation and Community Science at the Golden Gate National Parks Conservancy.  Allen is also the director of the Golden Gate Raptor Observatory since its founding in the mid 1980s. The Golden Gate Raptor Observatory is a four-decades-old community-science program of the Golden Gate National Parks Conservancy in cooperation with the National Park Service. It's set up to monitor the largest migration site for birds of prey in the Pacific Flyway.   Allen was a Lecturer at UC Davis from 2003 to 2011 where he taught Raptor Biology. Allen has a long history of writing and public speaking on raptor biology and conservation, urban wildlife ecology, climate change impacts, and the power of community science. Allen was awarded Bay Nature's Environmental Educator of the Year Award in 2016 and Golden Gate Audubon honored Allen with the Elsie Roemer Award for Conservation in 2020.   In 2011, Allen assisted Lisa in founding Raptors are the Solution. Allen lives with his family in Berkeley, and has recently become obsessed by the lives and ecology of dragonflies. Note: I was inspired to pursue this topic when I noticed that I wasn't hearing as many owls at night in my neighborhood. When disoriented rats began stumbling around our yard during the day and several were found dead in our yard, I did some research and discovered that rat poisons or anticoagulant rodenticides were the likely culprit-not only responsible for the dying and dead rats, but also for the decreased owl numbers. I decided to write an article Silent Night- The Unintended  Consequences of Rodenticides and in doing my research, I discovered Raptors Are the Solution (RATS). Links: Raptors Are the Solution or RATS Link to RATS Pilot Project in Seattle Article: Silent Night- The Unintended Consequences of Rodenticides

Do you love your medical podcasts, but sometimes wish your favourite shows would just team up for the odd awesome episode??Your ears are definitely in the right place.Jon and Barney are joined by brilliant MDTea hosts Dr Iain Wilkinson and Dr Stephen Collins. Together they deliver a masterclass in many aspects of elderly care and we uncover the greatest medical literature in the world! (From the last few months).1) Physical Activity in Hopital patients - They do too little but you can help.2) Bisphosphonates meta-analysis - harm v benefit.3) Mirtazapine in  patients with dementia - should we use?4) Subsegmental PEs - who cares about them?5) Lifelong anticoagulation - hard decisions need these facts. 6) Athletes at higher risk of AF - sorry!7) POCUS- can it change outcomes?Subscribe / rate on Spotify / Apple. Follow us on Twitter / Instagram. Send us FEEDBACK JournalSpotting@gmail.com. Share with your pals/colleagues/random groups on WhatsApp. 

FacultyTyree H. Kiser, PharmD, FCCM, FCCP, BCCCP, BCPSProfessor, Department of Clinical PharmacyUniversity of Colorado Skaggs School of Pharmacy and Pharmaceutical SciencesCritical Care Pharmacy Specialist, Department of PharmacyUniversity of Colorado HospitalAurora, ColoradoCharles E. “Kurt” Mahan, PharmD, PhC, FASHP, FCCPAdjunct Associate Professor, PharmacyUniversity of New Mexico Health Sciences CenterAlbuquerque, New Mexico  Content based on a CE activity supported by an educational grant from Alexion, AstraZeneca Rare Disease.  Link to full activity: https://www.proce.com/Anticoagulation

After a brief introduction, Dr. Dicks shares some of her encounters with medicinal leeches (2:29) before diving into the history of leech therapy (5:26). They then discuss contemporary hiroudotherapy practices (9:19) and some of the ethical implications of leech harvesting (14:45), closing with Dr. Dicks's leechiest film (23:40).

Warfarin is an anticoagulant that is also known by the brand name Coumadin. It is used in the treatment of myocardial infarction and thromboembolic complications. There is a wide variety of tablet strengths from 1 mg to as high as 10 mg. When dosing warfarin it is very patient-specific. The therapeutic goal is based on various factors and treatment nomograms may vary from institution to institution. Prior to initiation it is wise to establish the patient's genetic variant for CYP2C9 since this will play a large role in predicting their drug sensitivity. When attempting to reach a therapeutic target the healthcare professional uses INR readings to determine the level of anticoagulation. Generally a range between 2-3 is common with 2.5-3.5 when a high level of intensity is required. Other factors that may help determine patient response are age, race, and diet. The mechanism of action for warfarin lies in the antagonism of Vitamin K which leads toward the inhibition of coagulation factors 2, 7, 9, and 10. The rate-limiting factor can be seen as factor 2 due to it's long half-life of 60-72 hours. Although INR elevation can be seen in 24-48 hours, therapeutic benefits are not achieved until around 5-7 days after initiation. There is a black box warning for bleeding risk so a patient's INR should be monitored regularly. Go to DrugCardsDaily.com for episode show notes which consist of the drug summary, quiz, and link to the drug card for FREE! Please SUBSCRIBE, FOLLOW, and RATE on Spotify, Apple Podcasts, or wherever your favorite place to listen to podcasts are. The main goal is to go over the Top 200 Drugs with the occasional drug of interest. Also, if you'd like to say hello, suggest a drug, or leave some feedback I'd really appreciate hearing from you! Leave a voice message at anchor.fm/drugcardsdaily or find me on twitter @drugcardsdaily --- Send in a voice message: https://anchor.fm/drugcardsdaily/message

In December 2020, the American College of Cardiology published an Expert Consensus Decision Pathway for Antithrombotic Therapy in Patients undergoing Percutaneous Coronary Intervention. This guideline addresses a timely problem of patients on anticoagulation and antiplatelet therapy. This episode is accredited for CPE. Subscribe at CEimpact ( https://www.ceimpact.com/pharmacist ) and claim your CE today! Reference: 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. Dec 18, 2020. Epublished DOI: 10.1016/j.jacc.2020.09.011. Accessed at https://www.jacc.org/doi/10.1016/j.jacc.2020.09.011 CPE details for GameChangers Podcast January 2021 Learning Objective: Recommend an appropriate antithrombotic/anticoagulant regimen in a patient who has received percutaneous coronary intervention with stenting 0107-0000-21-079-H01-P 0.2 CEU/2.0 Hrs (Knowledge) Initial Release Date: 01/25/21 Expiration Date: 01/26/24 Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices

Anticoagulant rodenticides, specifically, brodifacoum, bromadiolone, difethialone, difenacoum, diphacinone and chlorophacinone, pose a serious threat to wildlife and ecosystems.

Show Notes Jeff: Welcome back to EMplify the podcast corollary to EB Medicine's Emergency medicine Practice. I'm Jeff Nusbaum and I'm back with Nachi Gupta. This month, we are tackling a topic for which the literature continues to rapidly change - we're talking about the ED management of patients taking direct oral anticoagulants or DOACs, previously called novel oral anticoagulants or NOACs. Nachi: Specifically, we'll be focusing on the use of DOACs for the indications of stroke prevention in atrial fibrillation and the treatment and prevention of recurrent venous thromboembolisms. Jeff: This month's article was authored by Dr. Patrick Maher and Dr. Emily Taub of the Icahn School of Medicine at Mount Sinai, and it was peer reviewed by Dr. Dowin Boatright from Yale, Dr. Natalie Kreitzer from the University of Cincinnati, and Dr. Isaac Tawil from the University of New Mexico. Nachi: In their quest to update the last Emergency Medicine Practice issue on this topic which was published in 2013, they reviewed over 200 articles from 2000 to present in addition to 5 systematic reviews in the cochrane database, as well as guidelines from the American Heart Association, European society of cardiology, and the american college of cardiology. Jeff: Thanks to a strong literature base, Dr's Maher and Taub found good quality evidence regarding safety and efficacy of the DOACs in relation to warfarin and the heparin-based anticoagulants. Nachi: But do note that the literature directly comparing the DOACs is far more limited and mostly of poor quality. Show More v Jeff: Fair enough, we'll take what we can get. Nachi: Well, I'm sure more of those studies are still coming. Jeff: Agree. Let's get started with some basics. Not surprisingly, DOACs now account for a similar proportion of office visits for anticoagulant use as warfarin. Nachi: With huge benefits including reduced need for monitoring and a potential for reduced bleeding complications, this certainly isn't surprising. Jeff: Though those benefits are not without challenges - most notably the lack of an effective reversal agent and the risk of unintentional overdose in patients with altered drug metabolism. Nachi: Like all things in medicine, it's about balancing and finding an acceptable risk/benefit profile. Jeff: True. Let's talk pathophysiology for a minute - the control of coagulation in the human body is a balance between hemorrhage and thrombosis, mediated by an extensive number of procoagulant and anticoagulant proteins. Nachi: Before the development of the DOACs, vitamin K antagonists controlled the brunt of the market. As their name suggests, they work by inhibiting the action of vitamin K, and thus reducing the production of clotting factors 2, 7, 9, and 10, and the anticoagulant proteins C and S. Jeff: Unfortunately, these agents have a narrow therapeutic window and many drug-drug interactions, and they require frequent monitoring - making them less desirable to many. Nachi: However, in 2010, the FDA approved the first DOAC, a real game-changer. The DOACs currently on the market work by one of two mechanisms - direct thrombin inhibition or factor Xa inhibition. Jeff: DOACs are currently approved for stroke prevention in nonvalvular afib, treatment of VTE, VTE prophylaxis, and reduction of major cardiovascular events in stable cardiovascular disease. Studies are underway to test their safety and efficacy in arterial and venous thromboembolism, prevention of embolic stroke in afib, ACS, cancer-associated thrombosis, upper extremity DVT, and mesenteric thrombosis. Nachi: Direct thrombin inhibitors like Dabigatran, tradename Pradaxa, was the first FDA approved DOAC. It works by directly inhibiting thrombin, or factor IIa, which is a serine protease that converts soluble fibrinogen into fibrin for clot formation. Jeff: Dabigatran comes in doses of 75 and 150 mg. The dose depends on your renal function, and, with a half-life of 12-15 hours,